Binex and MaxCyte collaborate for cancer research

Upon completion of the research studies, the agreement provides Binex an option to license MaxCyte’s technology for clinical and commercial use in Korea.

Baek Chun Lee, Binex’s chairman, said: “Our immunotherapy product is currently undergoing review by the Korean FDA for colorectal and non-small cell lung cancers, and clinical studies are in progress for breast and gastrointestinal cancers. We expect cell immunotherapies to continue to be a core business for Binex. As we advance this therapy, we are developing a closed system manufacturing process which will allow us to improve scalability and reduce cost for making inroads into world markets. We believe MaxCyte’s technology can contribute significantly as we expand this product toward new indications.”

Douglas Doerfler, president and CEO of MaxCyte, said: “We are extremely pleased to be working with Binex to advance their promising cancer vaccine. Our technology has been shown to be uniquely effective, capable of producing cell-based therapeutics that are highly reproducible, with the scalability and efficiency needed for commercial use. Binex’s readiness to partner with MaxCyte validates both the enablement of our cell loading technology platform and their leadership as a life sciences company.”